It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B.
The company announced the great news after the market closed on Thursday. Dynavax stock jumped on Friday, adding to year-to-date gains of close to 470%. But with shares already soaring so much this year, is it too late to buy Dynavax stock now that Heplisav-B has won approval? I don't think so.
Image source: Getty Images.
Source: Fool.com
Dynavax Technologies Corp Aktie
9,91 €
-0,26 %
Leichtes Buy-Überwiegen bei Dynavax Technologies Corp im Vergleich zu Sell-Einschätzungen.
Mit einem Community-Kursziel von 26 € für Dynavax Technologies Corp wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 9.91 € gesehen.
